Shares of Palantir Technologies slid 8.6% to $106.72 on Friday as a UK government watchdog publicly rebuked the way NHS England marketed the results of a data platform built on Palantir's software — striking at the heart of the company's highest-profile healthcare reference contract just as its renewal deadline approaches.
• The Watchdog Found the Numbers Don't Add Up. The Office for Statistics Regulation told NHS England to communicate more clearly about data used to measure the benefits of the Federated Data Platform, built on Palantir's technology under a £330 million contract.
The government and Palantir had long claimed the platform led to over 100,000 additional NHS operations, but an investigation by campaign group Foxglove revealed those benefits were unevenly distributed and, by NHS England's own admission, unsupported in terms of "cause and effect."
A Freedom of Information request found nearly a third of trusts using the platform were performing fewer patient procedures than before it went live.
• The Contract Faces a Kill Switch in Months. The deal follows a 3+2+1+1 structure; the initial three-year term ends in March 2027, and the health department must actively choose to extend it — otherwise it expires. That makes 2026 a critical decision year.
MPs on the Health and Social Care Committee have already urged the government to ditch Palantir at the break clause in February 2027, citing doubts about the platform's effectiveness. A downgraded credibility narrative makes renewal harder to justify politically.
• At 140x Earnings, There Is No Room for Contract Risk. Palantir trades at roughly 139–149 times trailing earnings and 65 times sales — a valuation that demands flawless execution. Second-quarter earnings arrive August 3 , and management will face pointed questions about international government pipeline durability. European markets are increasingly shifting toward domestic alternatives in sensitive sectors , and the NHS episode hands skeptics a tangible case study.
• The Real Money May Be Elsewhere, But the Optics Are Devastating. A former Palantir employee noted the NHS contract gets outsized attention relative to deals like the £1.5 billion Ministry of Defence agreement signed last year. That's fair — but the FDP is Palantir's most public proof point for healthcare AI. The contract represents a significant demonstration of the company's ability to deploy its technology within a major healthcare system. If that showcase is discredited, the pitch to every other national health service gets harder.